Focus:
US-based Deciphera Pharmaceuticals has signed an exclusive licence agreement with biopharmaceutical company Zai Lab to develop and commercialise cancer therapeutic ripretinib in Greater China.
Boehringer Ingelheim has extended a collaboration with the University of Dundee in Scotland for the development of proteolysis targeting chimera (PROTAC) based drugs to treat cancer.
Exscientia has entered a multi-target partnership with China-based GT Apeiron Therapeutics.
Scotland’s healthcare pricing regulator the Scottish Medicines Consortium (SMC) has decided to fund Bristol Myers-Squibb (BMS)’s Opdivo (nivolumab) plus Yervoy (ipilimumab) for use in NHS Scotland for renal cell carcinoma...
Merck has signed an agreement to buy biopharmaceutical company Tilos Therapeutics for a total consideration of up to $773m.
The US Federal Trade Commission (FTC) has requested that both Roche and Spark Therapeutics submit additional information and documentary material regarding their proposed merger agreement.
Genentech has received accelerated approval from the US Food and Drug Administration (FDA) for the use of Polivy (polatuzumab vedotin-piiq) in combination with bendamustine and rituximab (BR) to treat diffuse...
Sweden-based Calliditas Therapeutics has announced that Everest Medicines will commercialise its IgA nephropathy (IgAN) drug Nefecon in Greater China, which encompasses China, Hong Kong, Macau and Taiwan, and Singapore.
An advisory panel to the US Food and Drug Administration (FDA) has recommended the approval of TB Alliance’s investigational drug pretomanid in combination with bedaquiline and linezolid to treat drug-resistant...
Biogen has closed an acquisition of Nightstar Therapeutics for around $800m, marking its entry into the ophthalmology medicines market.
Go Top
